About Patatin-like phospholipase domain-containing protein 4
Patatin-like phospholipase domain-containing protein 4 (PNPLA4) is a protein
from Homo sapiens identified by UniProt accession
P41247, 253 residues long.
MolForge cross-references it against 0 known binders and
35 disease associations.
Target properties
| Protein name | Patatin-like phospholipase domain-containing protein 4 |
|---|
| UniProt accession | P41247 |
|---|
| Gene | PNPLA4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 253 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (35)
Diseases linked to this target (Open Targets).
- Abnormality of neuronal migration · score 0.11
- congenital heart disease · score 0.02
- head and neck squamous cell carcinoma · score 0.01
- systemic juvenile idiopathic arthritis · score 0.01
- atrial fibrillation · score 0.01
- hyperinsulinemic hypoglycemia, familial, 4 · score 0.01
- cancer · score 0.01
- Obesity · score 0.01
- Hyperlipidemia · score 0.01
- Anemia · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P41247-F1 | alphafold | PREDICTED | 94.42 | — |
Amino-acid sequence (253 residues)
MKHINLSFAA CGFLGIYHLG AASALCRHGK KLVKDVKAFA GASAGSLVAS VLLTAPEKIE ECNQFTYKFA EEIRRQSFGA VTPGYDFMAR LRSGMESILP PSAHELAQNR LHVSITNAKT RENHLVSTFS SREDLIKVLL ASSFVPIYAG LKLVEYKGQK WVDGGLTNAL PILPVGRTVT ISPFSGRLDI SPQDKGQLDL YVNIAKQDIM LSLANLVRLN QALFPPSKRK MESLYQCGFD DTVKFLLKEN WFE
Explore Patatin-like phospholipase domain-containing protein 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets